公开(公告)号：US20240279341A1

公开(公告)日：2024-08-22

申请号：US18570865

申请日：2022-06-15

Applicant: ALECTOR LLC

Inventor： Seung-Joo LEE ,  Tarangsri NIVITCHANYONG ,  Wei-Hsien HO ,  Wei LI ,  Marina K. ROELL ,  Spencer LIANG

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/40

CPC classification number: C07K16/2827 ,  A61P35/00 ,  C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure is generally directed to compositions that include bispecific antibodies, e.g., monoclonal antibodies, that specifically bind a MerTK polypeptide (e.g., a mammalian MerTK or human MerTK) and a PDL1 polypeptide (e.g. a mammalian PDL1 polypeptide or human PDL1 polypeptide), and use of such compositions in treating an individual in need thereof.

公开(公告)号：US20230220074A1

公开(公告)日：2023-07-13

申请号：US17904513

申请日：2021-02-17

Applicant: Alector LLC

Inventor： Spencer LIANG ,  Samuel NALLE ,  Ling LEUNG

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2827 ,  C07K2317/76 ,  A61K2039/507

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PILRA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.

公开(公告)号：US20240425587A1

公开(公告)日：2024-12-26

申请号：US18686156

申请日：2022-08-24

Applicant: ALECTOR LLC

Inventor： Samuel NALLE ,  Spencer LIANG ,  Ling LEUNG ,  Yong WANG ,  Angie Grace YEE

IPC: C07K16/28

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PILRA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand, block binding of soluble PILRA to T cells, and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.

公开(公告)号：US20240279358A1

公开(公告)日：2024-08-22

申请号：US18570888

申请日：2022-06-15

Applicant: ALECTOR LLC

Inventor： Seung-Joo LEE ,  Tarangsri NIVITCHANYONG ,  Wei-Hsien HO ,  Wei LI ,  Marina K. ROELL ,  Spencer LIANG

IPC: C07K16/40 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/40 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/53 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure is generally directed to compositions that include monovalent antibodies, e.g., monoclonal monovalent antibodies that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK polypeptide or human MerTK polypeptide, and use of such compositions in treating an individual in need thereof.

公开(公告)号：US20210261685A1

公开(公告)日：2021-08-26

申请号：US17118921

申请日：2020-12-11

Applicant: Alector LLC

Inventor： Seung-Joo LEE ,  Spencer LIANG ,  Angie YEE ,  Marina ROELL ,  Arnon ROSENTHAL

IPC: C07K16/40 ,  C07K16/28 ,  A61P35/00

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.